

# A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity

NCT07478822

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Chongqing Claruvis Pharmaceutical Co., Ltd.
Enrollment	300 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Age between 18 and 75 years old inclusive, at the time of signing the informed consent, regardless of gender.
- Subjects with unilateral hemiplegia due to stroke (with a time interval of e 3 months from stroke onset to enrollment) exhibiting upper limb spasticity.
- Subjects with Disability Assessment Scale score of at least 2 on the Principal Target of Treatment (one of four functional domains: hygiene, dressing, limb position and pain).

### Exclusion (9)

- History of allergy to any component of the experimental drugs.
  - Previous use of any botulinum toxin within 6 months prior to enrollment, or plan to use other botulinum toxins not specified in the study protocol during the study.
  - Fixed contractures of the studied limb.
  - Any medical condition that may increase the risk to the subject when using botulinum toxin type A.
  - Need for treatment with drugs that interfere with neuromuscular function during the study.
- ... and 4 more (see full listing online)

## Locations (16 total)

---

Peking Union Medical College Hospital, Beijing, China  
West China Hospital Sichuan University, Chengdu, China  
Guangdong Provincial People's Hospital, Guangdong, China  
... and 13 more locations